Prostate cancer is the second-leading cause of death in American men. However, prostate cancer is curable, thanks to options ...

Australian urologists are now using Orthocell’s flagship nerve repair product Remplir during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications caused ...

For 70-year-old grandfather Barry Henderson, the shock diagnosis of lung cancer hit quickly - but not as quickly as he was allowed to return home after receiving groundbreaking surgery.

Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce its flagship nerve repair device, Remplir, has been introduced to Urologists in Australia ...

Lucknow: Medanta Hospital in Lucknow conducted 509 robotic surgeries in the past year. Of the total, the gynaecology ...

Perth-based regenerative medicine company Orthocell (ASX:OCC) has announced its flagship nerve repair device Remplir has been introduced to urologists in Australia for use in nerve-sparing ...

Two regional cancer patients have become trailblazers for a cutting-edge procedure promising faster recovery, less pain and ...

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

The TULSA procedure is integral to our practice because it offers many men effective prostate treatment without the life-altering side effects of surgery — such as incontinence or erectile dysfunction ...

Dr. Mangesh Patil highlights the importance of early detection and innovative minimally invasive techniques in urological health for Urology Awareness Week 2025.

More good news has come out of this growing company. Orthocell Ltd shares climbed 10% to $1.21 following the announcement of a new application for its nerve repair device, Remplir, in prostate cancer ...